Suppr超能文献

丹参酮 IIA 通过下调 BCL2 和上调 TP53 促进三阴性乳腺癌细胞凋亡。

Tanshinone IIA promotes apoptosis by downregulating BCL2 and upregulating TP53 in triple-negative breast cancer.

机构信息

Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Tianjin, 300060, China.

Department of Traditional Chinese Medicine, General Hospital of Pingmei Shenma Group, Pingdingshan, 467000, China.

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb;396(2):365-374. doi: 10.1007/s00210-022-02316-1. Epub 2022 Nov 14.

Abstract

Tanshinone IIA (Tan IIA) was mainly used for cardiovascular disease treatment. Recent studies have demonstrated the role of Tan IIA for tumor treatment, but its mechanism remains unclear. At the first, the inhibitory effect of Tan IIA on 4T1 breast cancer cells was determined by CCK8 and colony formation assay. Then, a 4T1 BALB/c model of breast cancer was established to evaluate the anti-cancer effect of Tan IIA in vivo. Flow cytometry analysis and the TUNEL test were used to detect cell apoptosis in vitro and in vivo, respectively. The related targets and mechanisms of Tan IIA were predicted through network-based systems biology. At last, molecular docking and the molecular biological techniques were used to evaluate the predicted targets. Tan IIA displayed encouraging inhibitory influences on 4T1 cells after incubation for 24 h and showed a half-maximal inhibitory concentration (IC50) of 49.78 μM after 48-h incubation. After 23 days of treatment, the relative tumor volumes in the Tan IIA group were 65.53% inhibited compared with the control group. Furthermore, Tan IIA induced 4T1 cell apoptosis both in vivo and in vitro. The possible targets of Tan IIA for TNBC treatment were predicted with network-based systems biology, and results showed that TP53, NF-κB, AKT, MYC, and BCL-2 were the hub targets. The mechanism against breast cancer may be based on the P53 signaling pathway, the PI3K/Akt pathway, the MAPK signaling pathway, and the mTOR signaling pathways. Molecular docking analysis reveals that Tan IIA has a high affinity for p53, Bcl-2, and NF-κB1; the binding energies were - 6.92, - 6.07, and - 6.28 kcal/mol, respectively. The predicted proteins were further validated using Western blotting. Increased expression of phosphorylated p53 and p53 and decreased expression of Bcl-2 were found in Tan IIA-treated 4T1 cells. Tan IIA is potentially effective for the treatment of 4T1 breast cancer, and the molecular mechanism may be through enhancing the activity of p53 and decreasing Bcl-2 to suppress proliferation and promote apoptosis.

摘要

丹参酮 IIA(Tan IIA)主要用于治疗心血管疾病。最近的研究表明,Tan IIA 可用于肿瘤治疗,但作用机制尚不清楚。首先,通过 CCK8 和集落形成实验确定 Tan IIA 对 4T1 乳腺癌细胞的抑制作用。然后,建立 4T1 BALB/c 乳腺癌模型,在体内评估 Tan IIA 的抗癌作用。通过流式细胞术分析和 TUNEL 试验分别检测细胞凋亡。通过基于网络的系统生物学预测 Tan IIA 的相关靶点和作用机制。最后,使用分子对接和分子生物学技术评估预测靶点。Tan IIA 孵育 24 h 后对 4T1 细胞表现出令人鼓舞的抑制作用,孵育 48 h 后半最大抑制浓度(IC50)为 49.78 μM。治疗 23 天后,Tan IIA 组的相对肿瘤体积与对照组相比抑制了 65.53%。此外,Tan IIA 在体内和体外均诱导 4T1 细胞凋亡。通过基于网络的系统生物学预测 Tan IIA 治疗三阴性乳腺癌的可能靶点,结果表明 TP53、NF-κB、AKT、MYC 和 BCL-2 是枢纽靶点。针对乳腺癌的机制可能基于 P53 信号通路、PI3K/Akt 通路、MAPK 信号通路和 mTOR 信号通路。分子对接分析表明,Tan IIA 与 p53、Bcl-2 和 NF-κB1 具有高亲和力;结合能分别为-6.92、-6.07 和-6.28 kcal/mol。进一步使用 Western blot 验证预测蛋白。在 Tan IIA 处理的 4T1 细胞中发现磷酸化 p53 和 p53 表达增加,Bcl-2 表达减少。Tan IIA 可能对治疗 4T1 乳腺癌有效,其分子机制可能是通过增强 p53 的活性和降低 Bcl-2 来抑制增殖并促进凋亡。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验